http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-200301119-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07b71571160c289fbf5fc680dfea513f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2002-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e860ebc6a47312fa65e488acf34df4ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebf262557175e20f51c9e19c5d7209ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d4f5408a12cda5bfe6382a42fa3211f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_288611482e1ff5cdc6388b792d707cf1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efde2afe07c2ac4197d909f05e089313 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80fc5d75dec85a5f58194b6479141558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_822000062588fc9f125419c5c64cf20f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56ea18ac7e16550e3556ab2f934413d4 |
| publicationDate | 2003-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-200301119-A |
| titleOfInvention | Chemical compounds |
| abstract | Fused pyradazine derivatives, which are useful as CDK inhibitors are described herein. The described invention also includes methods of making, such fused pyradazines derivatives as well as methods of using the same in the treatment of hyperproliferative diseases. A compound of Formula (I): or a salt, solvate, or physiologically functional derivative thereof: wherein D is N or CH R1 is hydrogen, C1-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl C1-C3 alkoxy, halogen, -CF3, hydroxy, cyano, -S(O)yC1-C3 alkyl, or -NR4R5; y is 0, 1, or 2; a is 1 or 2; R2 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, halogen heterocyclyl, aryl, heteroaryl, cyano, azido, nitro, -OR8, -OR6R8, -R6R7, -R6R'', -OS(O)2R9, -S(O)yR10, -C(O)R7, -C(O)OR7, C(O)NR4R5, -N(H)R'C(=NR4) NR4R5, -OC(O)NR4R5, -OC(O)OR7, -C(=NR4)NR4R5, -NR4R5, -NR4R5, -OC(O)R7, or -N(R8)C(O)R8; R3 is -(Q)p-(Q1) where Q is O, N(R8) or S(O)y, p is 0 or 1, y is 0, 1, or 2 and Q1 is C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl, aryl, aryl substituted with -C(O)N(H)R6NR4R5 or -OC(H)(OH)R6NR4R5, heteroaryl, aralkyl, or -R6NR4R5; R4 and R5 are independently hydrogen, C1-C3 alkyl, C3-C7 cycloalkyl, -C(O)R9, or R4 and R5, together with the nitrogen atom to which they are bound, form a heterocyclyl; R6 is alkylene, arylene, heteroarylene, C3-C7 cycloalkylene, alkenylene, C3-C7 cycloalkenylene, or alkynylene; R7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -NR4R5, aryl, aralkyl, heteroaryl, cycloalkyl, heterocyclyl, -S(O)yR10, -C(O)R8, -C(O)R8, -C(O)NR4R5, -S(O)2NR4R5, -N(H)R'C(=NR4)NR4R5, -OC(O)NR4R5, -OC(O)OR8, -C(=NR4)NR4R5, -NR4R5, -or -N(R8)C(O)R8; R8 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -NR4R5, aryl, aralkyl, heteroaryl, cycloalky heterocyclyl, or -S(O)2R9; R9 is C1-C6 alkyl or C1-C6 haloalkyl; R10 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -NR4R5, aryl, aralkyl, heteroaryl, cycloalkyl, heterocyclyl, -C(O)R8, -C(O)OR8, -C(O)NR4R5, -N(H)R'C(=NR4)NR4R5, -OC(O)NR4R5, -OC(O)OR8, -C(=NR4)NR4R5, -NR4R5, or -N(R8)C(O)R8; R' is C1-C3 alkylene; and R'' is -OR7, -OC(O)NR4R5, -OC(O)OR7, or -OC(O)R7. |
| priorityDate | 2001-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 547.